EPISODE · Feb 4, 2026 · 17 MIN
Novo Nordisk 2025 Annual Performance and 2026 Strategic Outlook
from Daily Market Download · host Daily Market Download
In 2025, Novo Nordisk achieved 10% sales growth, reaching DKK 309 billion, primarily driven by a 31% surge in obesity care. Key developments include the Wegovy pill launch and pipeline assets like CagriSema. The firm announced a DKK 15 billion share buyback and increased dividends.
What this episode covers
In 2025, Novo Nordisk achieved 10% sales growth, reaching DKK 309 billion, primarily driven by a 31% surge in obesity care. Key developments include the Wegovy pill launch and pipeline assets like CagriSema. The firm announced a DKK 15 billion share buyback and increased dividends.
NOW PLAYING
Novo Nordisk 2025 Annual Performance and 2026 Strategic Outlook
No transcript for this episode yet
Similar Episodes
Jun 15, 2022 ·8m
May 25, 2022 ·20m
May 19, 2022 ·16m
May 15, 2022 ·34m
May 12, 2022 ·1m